Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poziotinib + ado-trastuzumab emtansine
- Development stage
- Preclinical
- Lead developer
- Assertio
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**poziotinib + ado-trastuzumab emtansine** is a combination investigational therapy for HER2-positive cancers. Poziotinib is an orally available, irreversible small molecule tyrosine kinase inhibitor targeting HER2 (ERBB2), EGFR (ERBB1), and HER4 (ERBB4) receptors. Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate composed of trastuzumab (a monoclonal antibody targeting HER2) linked to DM1 (a cytotoxic maytansine derivative) via a stable linker; it delivers targeted cytotoxic activity directly to HER2-overexpressing cells. This combination is proposed to provide dual HER2 blockade: poziotinib inhibits signaling through HER-family receptors, while ado-trastuzumab emtansine induces targeted cytotoxicity. The primary indication is treatment of advanced or metastatic HER2-positive breast cancer, particularly after progression on prior HER2-targeted therapies.
- Other names
- poziotinib + T-DM1poziotinib plus ado-trastuzumab emtansine
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on poziotinib + ado-trastuzumab emtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poziotinib + ado-trastuzumab emtansine.